Cargando…

Introduction of managed entry agreements in Korea: Problem, policy, and politics

Objectives: This study aimed to understand Managed Entry Agreements (MEAs) in Korea through the framework of three streams of the policy window model and its practical management and impact on pricing and reimbursement scheme. Methods: An extensive literature review based on Kingdon’s model was cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyungmin, Godman, Brian, Kwon, Hye-Young, Hong, Song Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133550/ https://www.ncbi.nlm.nih.gov/pubmed/37124231 http://dx.doi.org/10.3389/fphar.2023.999220

Ejemplares similares

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future
por: Pauwels, Kim, et al.
Publicado: (2017)

The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy
por: Xoxi, Entela, et al.
Publicado: (2021)

Managed entry agreements
por: Muscolo, Luisa AA, et al.
Publicado: (2014)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
por: Ferrario, Alessandra, et al.
Publicado: (2017)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
por: Vella Bonanno, Patricia, et al.
Publicado: (2021)

Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications
por: Kwon, Hye-Young, et al.
Publicado: (2016)

Erratum to: Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications
por: Kwon, Hye-Young, et al.
Publicado: (2017)

Potential to Enhance the Prescribing of Generic Drugs in Patients with Mental Health Problems in Austria; Implications for the Future
por: Godman, Brian, et al.
Publicado: (2013)

Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province
por: Matlala, Moliehi, et al.
Publicado: (2020)

Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data
por: Kwon, Sun-Hong, et al.
Publicado: (2022)

Reverse Triggering: An Introduction to Diagnosis, Management, and Pharmacologic Implications
por: Murray, Brian, et al.
Publicado: (2022)

Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and Policy
por: Fens, Tanja, et al.
Publicado: (2021)

What is synergy? The Saariselkä agreement revisited
por: Tang, Jing, et al.
Publicado: (2015)

Management of Contacts of the First Imported Monkeypox Case in Korea
por: Shin, Minjoung, et al.
Publicado: (2022)

Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience
por: Ciulla, Michele, et al.
Publicado: (2023)

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
por: Godman, Brian, et al.
Publicado: (2011)

The Multiple Streams Framework: Understanding and Applying the Problems, Policies, and Politics Approach
por: Hoefer, Richard
Publicado: (2022)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
por: Lee, Mijin, et al.
Publicado: (2023)

The politics of multilateral environmental agreements lessons from 20 years of INEA
por: Kalfagianni, Agni, et al.
Publicado: (2022)

How Do Iranian Stakeholders Think About Pharmaceutical Managed Entry Agreements?
por: Shobeiri, Nikta, et al.
Publicado: (2022)

Stakeholder views of managed entry agreements: A literature review of national studies
por: Thanimalai, Subramaniam, et al.
Publicado: (2021)

Introduction to global politics
por: Mansbach, Richard W, et al.
Publicado: (2012)

Spanning the boundaries between policy, politics and science to solve wicked problems: policy pilots, deliberation fora and policy labs
por: Zeigermann, Ulrike, et al.
Publicado: (2022)

Antimicrobial Medicines Consumption in Eastern Europeand Central Asia – An Updated Cross-National Study and Assessment of QuantitativeMetrics for Policy Action
por: Robertson, Jane, et al.
Publicado: (2019)

Repositories, policy and politics
por: Prosser, David
Publicado: (2007)

Repositories, policy and politics
por: Prosser, David, et al.
Publicado: (2007)

Circular Agreements—Exploring the Role of Agreements and Deals as a Political Tool for a Circular Economy
por: Johansson, Nils
Publicado: (2021)

Italian Immunization Goals: A Political or Scientific Heated Debate?
por: Scavone, Cristina, et al.
Publicado: (2018)

Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions
por: Gad, Mohamed, et al.
Publicado: (2020)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Agreement on pork problems.
Publicado: (1998)

Impact of national policy on hand hygiene promotion activities in hospitals in Korea
por: Choe, Pyoeng Gyun, et al.
Publicado: (2020)

Medicine Shortages: Gaps Between Countries and Global Perspectives
por: Acosta, Angela, et al.
Publicado: (2019)

Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
por: Facey, Karen M., et al.
Publicado: (2021)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tnrv4bs5ogauk2gjsm3tfe8c6f